Solid stock: buy or sell?

SLDB stock price: $9.30 5.56% At close on August 19th, 2019

Updated on:
August 19th, 2019


After crossing up the simple moving average line of 100d yesterday, Solid Biosciences closed at $9.30, rocketed a 5.56%. On Tuesday SLDB plunged a scary -12.38%.

Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States.

Should I buy Solid stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

None of our preferred buy setups matches with Solid Biosciences stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Solid stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we detected 8 ratings published for SLDB stock in the last month.

Is SLDB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-19Svb LeerinkMarket PerformOutperform
2019-8-19Leerink SwannMarket PerformOutperform
2019-8-16Chardan CapitalNeutralBuy
2019-5-14Goldman Sachs GroupNeutralSell
2019-5-14Credit Suisse GroupNeutralUnderperform
2019-2-8Svb LeerinkOutperformMarket Perform
2019-2-7Chardan Capitaln/aBuy

Solid stock analysis

Daily outlook

After breaking up the SMA line of 100 days yesterday, Solid Biosciences closed at $9.30.

After breaking up the simple moving average line of 100d yesterday, Solid Biosciences closed today at $9.30, rocketed a 5.56%.

SLDB stock chart (daily)

Weekly outlook

Solid shares skyrocketed 5.56% this week, ending at $9.30. By mid July SLDB plunged a bloodcurdling -11.55% in just one week.

Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $6.87 resistance.

SLDB stock chart (weekly)

Solid stock price history

Solid IPO was on January 26th, 2018 at $25.50 per share1. Since then, SLDB stock declined a -63.50%, with a yearly average of -63.50%.

1: Adjusted price after possible price splits or reverse-splits.

Solid stock historical price chart

SLDB stock reached 52-week highs on September at $54.54, and all-time highs 2018-06-19 with a price of 54.84.

Solid stock price target is $10.30

Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last month we found 3 price predictions for SLDB stock:
SLDB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-16Chardan CapitalUpgrades$7.50$10.0033.3%
2019-5-14Credit Suisse GroupDowngrades$7.00$6.00-14.3%
2019-2-7Chardan CapitalReiteratesn/a$15.00-
(in average)$7.30$10.3041.0%
Moving in a range from $15.00 and $6.00, the price prediction for SLDB stock is $10.30. In average, analysts' outlook on SLDB price target is positive, increasing the target by a 41.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On March, Solid reported its latest financial data, posting a pretty good climb for the Earnings per Share (EPS). Experts expected $-0.58 per share, but Solid posted $-0.67.
SLDB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In , Solid Biosciences annual revenues to million USD from marked in . , its income margin (compared to revenues) to , that is million.

SLDB annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-21.92 million with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Solid Biosciences sales marked a neutral movement and stayed steady a nan%. Looking back to recent quarterly results, Solid posted 5 positive quarters in a row.
SLDB quarterly Sales and Income evolution

Solid ownership

When you are planning to buy shares of a stock, it's worth to review its ownership structure.

Solid Biosciences shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 34.71% of all shares.

In case of Solid Biosciences stock, 77.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SLDB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Solid:

Market cap$329.3 M
Total shares35.4 M
Float shares3.6 M
  - Institutional holdings (%)77.4%
  - Insider holdings (%)34.7%
Shares in short selling0.0%

Solid summary

Monday, August 19th, 2019
Day range$9.03 - $10.48
Previous close$8.81
Session gain5.56%
Average true range$0.93
50d mov avg$5.47
100d mov avg$6.74
200d mov avg$14.31
Daily pattern
Weekly pattern lb02c

Solid performance

To measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Solid Biosciences performance to :
SLDBSolid Biosciences68.48%3.79%-75.74%

Solid competitors

Unfortunately, we could not find any public company that could be defined as Solid competitor. This doesn't mean Solid does not have any competitor in the market, it's just we could not detected it.